A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers
The objective of this study was to summarize all clinical studies evaluating the prognostic role of gemcitabine (GEM) metabolic genes in pancreaticobiliary (PB) cancer patients receiving GEM therapy in the neoadjuvant, adjuvant, or palliative settings. Meta-analyses were performed to calculate the p...
Gespeichert in:
| Veröffentlicht in: | Pancreas 2013-11, Vol.42 (8), p.1303-1310 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1310 |
|---|---|
| container_issue | 8 |
| container_start_page | 1303 |
| container_title | Pancreas |
| container_volume | 42 |
| creator | Wei, Christina H Gorgan, Tristan R Elashoff, David A Hines, O Joe Farrell, James J Donahue, Timothy R |
| description | The objective of this study was to summarize all clinical studies evaluating the prognostic role of gemcitabine (GEM) metabolic genes in pancreaticobiliary (PB) cancer patients receiving GEM therapy in the neoadjuvant, adjuvant, or palliative settings.
Meta-analyses were performed to calculate the pooled hazard ratios for each gene by each clinical outcome (overall survival [OS], disease-free survival [DFS], and progression-free survival) using a random-effects approach.
The search strategy identified 16 eligible studies, composed of 632 PB patients total, with moderate quality. Compared with low expression, pooled hazard ratios for OS of hENT1, dCK, RRM1, RRM2, and DPD were 0.37 (95% confidence interval [CI], 0.28-0.47), 0.40 (95% CI, 0.20-0.80), 2.21 (95% CI, 1.12-4.36), 2.13 (95% CI, 1.00-4.52), and 1.91 (95% CI, 1.16-3.17), respectively. A similar trend was observed for each of these biomarkers in DFS and progression-free survival prognostication. Subgroup analyses for hENT1 showed a comparable survival correlation in the adjuvant and palliative settings.
High expression of hENT1 in PB cancer patients receiving GEM-based adjuvant therapy is associated with improved OS and DFS and may be the best examined prognostic marker to date. Evidence for other biomarkers is limited by a small number of publications investigating these markers. |
| doi_str_mv | 10.1097/MPA.0b013e3182a23ae4 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_MPA_0b013e3182a23ae4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>24152955</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-5fd7c94f49b2ceb299523a899284f6f2313aaebbfc9d98be7d49b30b0d63747b3</originalsourceid><addsrcrecordid>eNpdkN1KAzEQhYMotlbfQCQvsDXJJE1yWYp_oOiFvV6S7ESj3d2yWZG-vZGqF14NczhnmPMRcs7ZnDOrLx-elnPmGQcEboQT4FAekClXsKikEeaQTJkxqgKu9YSc5PzGGNeg7DGZCMmVsEpNyXpJWxxd5Tq32eWUaR_pC7Yhjc6nDqlPfeuGdxwyTR3dujFhN2b6mcbXsnVhwCKF3qdNcsOOhiIV7yk5im6T8exnzsj6-up5dVvdP97crZb3VQAFY6Vio4OVUVovAnphrSo1jLXCyLiIAjg4h97HYBtrPOqmOKGUbhagpfYwI3J_Nwx9zgPGejuk8u-u5qz-plQXSvV_SiV2sY9tP3yLzV_oFwt8AdFgZkM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Wei, Christina H ; Gorgan, Tristan R ; Elashoff, David A ; Hines, O Joe ; Farrell, James J ; Donahue, Timothy R</creator><creatorcontrib>Wei, Christina H ; Gorgan, Tristan R ; Elashoff, David A ; Hines, O Joe ; Farrell, James J ; Donahue, Timothy R</creatorcontrib><description>The objective of this study was to summarize all clinical studies evaluating the prognostic role of gemcitabine (GEM) metabolic genes in pancreaticobiliary (PB) cancer patients receiving GEM therapy in the neoadjuvant, adjuvant, or palliative settings.
Meta-analyses were performed to calculate the pooled hazard ratios for each gene by each clinical outcome (overall survival [OS], disease-free survival [DFS], and progression-free survival) using a random-effects approach.
The search strategy identified 16 eligible studies, composed of 632 PB patients total, with moderate quality. Compared with low expression, pooled hazard ratios for OS of hENT1, dCK, RRM1, RRM2, and DPD were 0.37 (95% confidence interval [CI], 0.28-0.47), 0.40 (95% CI, 0.20-0.80), 2.21 (95% CI, 1.12-4.36), 2.13 (95% CI, 1.00-4.52), and 1.91 (95% CI, 1.16-3.17), respectively. A similar trend was observed for each of these biomarkers in DFS and progression-free survival prognostication. Subgroup analyses for hENT1 showed a comparable survival correlation in the adjuvant and palliative settings.
High expression of hENT1 in PB cancer patients receiving GEM-based adjuvant therapy is associated with improved OS and DFS and may be the best examined prognostic marker to date. Evidence for other biomarkers is limited by a small number of publications investigating these markers.</description><identifier>ISSN: 0885-3177</identifier><identifier>EISSN: 1536-4828</identifier><identifier>DOI: 10.1097/MPA.0b013e3182a23ae4</identifier><identifier>PMID: 24152955</identifier><language>eng</language><publisher>United States</publisher><subject>Antimetabolites, Antineoplastic - therapeutic use ; Biliary Tract Neoplasms - drug therapy ; Biliary Tract Neoplasms - genetics ; Biomarkers, Tumor - genetics ; Chemotherapy, Adjuvant ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Deoxycytidine Kinase - genetics ; Disease-Free Survival ; Equilibrative Nucleoside Transporter 1 - genetics ; Gene Expression Regulation, Neoplastic - drug effects ; Humans ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - genetics ; Prognosis ; Ribonucleoside Diphosphate Reductase - genetics ; Tumor Suppressor Proteins - genetics</subject><ispartof>Pancreas, 2013-11, Vol.42 (8), p.1303-1310</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-5fd7c94f49b2ceb299523a899284f6f2313aaebbfc9d98be7d49b30b0d63747b3</citedby><cites>FETCH-LOGICAL-c353t-5fd7c94f49b2ceb299523a899284f6f2313aaebbfc9d98be7d49b30b0d63747b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24152955$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wei, Christina H</creatorcontrib><creatorcontrib>Gorgan, Tristan R</creatorcontrib><creatorcontrib>Elashoff, David A</creatorcontrib><creatorcontrib>Hines, O Joe</creatorcontrib><creatorcontrib>Farrell, James J</creatorcontrib><creatorcontrib>Donahue, Timothy R</creatorcontrib><title>A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers</title><title>Pancreas</title><addtitle>Pancreas</addtitle><description>The objective of this study was to summarize all clinical studies evaluating the prognostic role of gemcitabine (GEM) metabolic genes in pancreaticobiliary (PB) cancer patients receiving GEM therapy in the neoadjuvant, adjuvant, or palliative settings.
Meta-analyses were performed to calculate the pooled hazard ratios for each gene by each clinical outcome (overall survival [OS], disease-free survival [DFS], and progression-free survival) using a random-effects approach.
The search strategy identified 16 eligible studies, composed of 632 PB patients total, with moderate quality. Compared with low expression, pooled hazard ratios for OS of hENT1, dCK, RRM1, RRM2, and DPD were 0.37 (95% confidence interval [CI], 0.28-0.47), 0.40 (95% CI, 0.20-0.80), 2.21 (95% CI, 1.12-4.36), 2.13 (95% CI, 1.00-4.52), and 1.91 (95% CI, 1.16-3.17), respectively. A similar trend was observed for each of these biomarkers in DFS and progression-free survival prognostication. Subgroup analyses for hENT1 showed a comparable survival correlation in the adjuvant and palliative settings.
High expression of hENT1 in PB cancer patients receiving GEM-based adjuvant therapy is associated with improved OS and DFS and may be the best examined prognostic marker to date. Evidence for other biomarkers is limited by a small number of publications investigating these markers.</description><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Biliary Tract Neoplasms - drug therapy</subject><subject>Biliary Tract Neoplasms - genetics</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Chemotherapy, Adjuvant</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Deoxycytidine Kinase - genetics</subject><subject>Disease-Free Survival</subject><subject>Equilibrative Nucleoside Transporter 1 - genetics</subject><subject>Gene Expression Regulation, Neoplastic - drug effects</subject><subject>Humans</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - genetics</subject><subject>Prognosis</subject><subject>Ribonucleoside Diphosphate Reductase - genetics</subject><subject>Tumor Suppressor Proteins - genetics</subject><issn>0885-3177</issn><issn>1536-4828</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkN1KAzEQhYMotlbfQCQvsDXJJE1yWYp_oOiFvV6S7ESj3d2yWZG-vZGqF14NczhnmPMRcs7ZnDOrLx-elnPmGQcEboQT4FAekClXsKikEeaQTJkxqgKu9YSc5PzGGNeg7DGZCMmVsEpNyXpJWxxd5Tq32eWUaR_pC7Yhjc6nDqlPfeuGdxwyTR3dujFhN2b6mcbXsnVhwCKF3qdNcsOOhiIV7yk5im6T8exnzsj6-up5dVvdP97crZb3VQAFY6Vio4OVUVovAnphrSo1jLXCyLiIAjg4h97HYBtrPOqmOKGUbhagpfYwI3J_Nwx9zgPGejuk8u-u5qz-plQXSvV_SiV2sY9tP3yLzV_oFwt8AdFgZkM</recordid><startdate>201311</startdate><enddate>201311</enddate><creator>Wei, Christina H</creator><creator>Gorgan, Tristan R</creator><creator>Elashoff, David A</creator><creator>Hines, O Joe</creator><creator>Farrell, James J</creator><creator>Donahue, Timothy R</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201311</creationdate><title>A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers</title><author>Wei, Christina H ; Gorgan, Tristan R ; Elashoff, David A ; Hines, O Joe ; Farrell, James J ; Donahue, Timothy R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-5fd7c94f49b2ceb299523a899284f6f2313aaebbfc9d98be7d49b30b0d63747b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Biliary Tract Neoplasms - drug therapy</topic><topic>Biliary Tract Neoplasms - genetics</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Chemotherapy, Adjuvant</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Deoxycytidine Kinase - genetics</topic><topic>Disease-Free Survival</topic><topic>Equilibrative Nucleoside Transporter 1 - genetics</topic><topic>Gene Expression Regulation, Neoplastic - drug effects</topic><topic>Humans</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - genetics</topic><topic>Prognosis</topic><topic>Ribonucleoside Diphosphate Reductase - genetics</topic><topic>Tumor Suppressor Proteins - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wei, Christina H</creatorcontrib><creatorcontrib>Gorgan, Tristan R</creatorcontrib><creatorcontrib>Elashoff, David A</creatorcontrib><creatorcontrib>Hines, O Joe</creatorcontrib><creatorcontrib>Farrell, James J</creatorcontrib><creatorcontrib>Donahue, Timothy R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Pancreas</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wei, Christina H</au><au>Gorgan, Tristan R</au><au>Elashoff, David A</au><au>Hines, O Joe</au><au>Farrell, James J</au><au>Donahue, Timothy R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers</atitle><jtitle>Pancreas</jtitle><addtitle>Pancreas</addtitle><date>2013-11</date><risdate>2013</risdate><volume>42</volume><issue>8</issue><spage>1303</spage><epage>1310</epage><pages>1303-1310</pages><issn>0885-3177</issn><eissn>1536-4828</eissn><abstract>The objective of this study was to summarize all clinical studies evaluating the prognostic role of gemcitabine (GEM) metabolic genes in pancreaticobiliary (PB) cancer patients receiving GEM therapy in the neoadjuvant, adjuvant, or palliative settings.
Meta-analyses were performed to calculate the pooled hazard ratios for each gene by each clinical outcome (overall survival [OS], disease-free survival [DFS], and progression-free survival) using a random-effects approach.
The search strategy identified 16 eligible studies, composed of 632 PB patients total, with moderate quality. Compared with low expression, pooled hazard ratios for OS of hENT1, dCK, RRM1, RRM2, and DPD were 0.37 (95% confidence interval [CI], 0.28-0.47), 0.40 (95% CI, 0.20-0.80), 2.21 (95% CI, 1.12-4.36), 2.13 (95% CI, 1.00-4.52), and 1.91 (95% CI, 1.16-3.17), respectively. A similar trend was observed for each of these biomarkers in DFS and progression-free survival prognostication. Subgroup analyses for hENT1 showed a comparable survival correlation in the adjuvant and palliative settings.
High expression of hENT1 in PB cancer patients receiving GEM-based adjuvant therapy is associated with improved OS and DFS and may be the best examined prognostic marker to date. Evidence for other biomarkers is limited by a small number of publications investigating these markers.</abstract><cop>United States</cop><pmid>24152955</pmid><doi>10.1097/MPA.0b013e3182a23ae4</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3177 |
| ispartof | Pancreas, 2013-11, Vol.42 (8), p.1303-1310 |
| issn | 0885-3177 1536-4828 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_MPA_0b013e3182a23ae4 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Antimetabolites, Antineoplastic - therapeutic use Biliary Tract Neoplasms - drug therapy Biliary Tract Neoplasms - genetics Biomarkers, Tumor - genetics Chemotherapy, Adjuvant Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Deoxycytidine Kinase - genetics Disease-Free Survival Equilibrative Nucleoside Transporter 1 - genetics Gene Expression Regulation, Neoplastic - drug effects Humans Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Prognosis Ribonucleoside Diphosphate Reductase - genetics Tumor Suppressor Proteins - genetics |
| title | A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A38%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20meta-analysis%20of%20gemcitabine%20biomarkers%20in%20patients%20with%20pancreaticobiliary%20cancers&rft.jtitle=Pancreas&rft.au=Wei,%20Christina%20H&rft.date=2013-11&rft.volume=42&rft.issue=8&rft.spage=1303&rft.epage=1310&rft.pages=1303-1310&rft.issn=0885-3177&rft.eissn=1536-4828&rft_id=info:doi/10.1097/MPA.0b013e3182a23ae4&rft_dat=%3Cpubmed_cross%3E24152955%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/24152955&rfr_iscdi=true |